Selective HCN1 block as a strategy to control oxaliplatin-induced neuropathy.
Resta F, Micheli L, Laurino A, Spinelli V, Mello T, Sartiani L, Di Cesare Mannelli L, Cerbai E, Ghelardini C, Romanelli MN, Mannaioni G, Masi A.
Resta F, et al. Among authors: sartiani l.
Neuropharmacology. 2018 Mar 15;131:403-413. doi: 10.1016/j.neuropharm.2018.01.014. Epub 2018 Jan 12.
Neuropharmacology. 2018.
PMID: 29339292